Tianyin Pharma gets Chinese nod for Snaqi & Yinqiao Jiedu tabs

Tianyin Pharmaceutical Co, Inc, a manufacturer and supplier of modernized traditional Chinese medicine (TCM) based in Chengdu, China, has received approvals from the Chinese State Food and Drug Administration (SFDA) to produce Sanqi tablets in dosage form of 0.5 gram/tablet (SFDA approval number Z20093512) and Yinqiao Jiedu tablets in dosage form of 0.5 gram/tablet (SFDA approval number Z20093555). 

Sanqi Tablets are a generic TCM that effectively treats traumatic injuries and stops bleeding without causing blood stasis, while also alleviating associated pain and reducing swelling. Sanqi is also used as a haemostatic for patients with internal bleeding or hemorrhagic diseases. According to Tianyin's market research and estimation, annual sales of Sanqi are approximately $73.5 million in China. Tianyin expects to gain a portion of the market share in orthopedic medicine through the production and marketing of Sanqi Tablets.